CA2753532A1 - Derives de nicotinamide - Google Patents

Derives de nicotinamide Download PDF

Info

Publication number
CA2753532A1
CA2753532A1 CA2753532A CA2753532A CA2753532A1 CA 2753532 A1 CA2753532 A1 CA 2753532A1 CA 2753532 A CA2753532 A CA 2753532A CA 2753532 A CA2753532 A CA 2753532A CA 2753532 A1 CA2753532 A1 CA 2753532A1
Authority
CA
Canada
Prior art keywords
compound
atom
group
radiohalogen
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2753532A
Other languages
English (en)
Inventor
Andrew Katsifis
Ivan Greguric
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRC for Biomedical Imaging Development Ltd
Original Assignee
CRC for Biomedical Imaging Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008901989A external-priority patent/AU2008901989A0/en
Application filed by CRC for Biomedical Imaging Development Ltd filed Critical CRC for Biomedical Imaging Development Ltd
Publication of CA2753532A1 publication Critical patent/CA2753532A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2753532A 2008-04-22 2009-04-22 Derives de nicotinamide Abandoned CA2753532A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008901989 2008-04-22
AU2008901989A AU2008901989A0 (en) 2008-04-22 Nicotinamide derivatives
PCT/AU2009/000504 WO2009129573A1 (fr) 2008-04-22 2009-04-22 Dérivés de nicotinamide

Publications (1)

Publication Number Publication Date
CA2753532A1 true CA2753532A1 (fr) 2009-10-29

Family

ID=41216339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2753532A Abandoned CA2753532A1 (fr) 2008-04-22 2009-04-22 Derives de nicotinamide

Country Status (6)

Country Link
EP (1) EP2285778A4 (fr)
CN (1) CN102232067A (fr)
AU (1) AU2009240785A1 (fr)
CA (1) CA2753532A1 (fr)
NZ (1) NZ589360A (fr)
WO (1) WO2009129573A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120107240A1 (en) * 2010-11-03 2012-05-03 The Board Of Trustees Of The Leland Stanford Junior University Probes and methods of melanoma imaging
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
JP2015193545A (ja) * 2014-03-31 2015-11-05 国立大学法人京都大学 ２−（３−ピリジニル）−１ｈ−ベンズイミダゾール誘導体化合物、これを含む放射性医薬
CN107556236B (zh) * 2017-08-25 2020-01-21 华中科技大学同济医学院附属协和医院 同位素取代的靶向黑色素瘤的正电子显像剂及其制备方法与用途
KR102302065B1 (ko) * 2018-06-28 2021-09-15 전남대학교 산학협력단 흑색종 치료용 방사성 화합물 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2904317A1 (fr) * 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
EP2085390A1 (fr) * 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Analogues d'halobenzamide marqués en tant que produits radiopharmaceutiques multimodaux et leurs précurseurs

Also Published As

Publication number Publication date
WO2009129573A1 (fr) 2009-10-29
AU2009240785A1 (en) 2009-10-29
EP2285778A4 (fr) 2011-05-11
CN102232067A (zh) 2011-11-02
EP2285778A1 (fr) 2011-02-23
NZ589360A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
EP2321279B1 (fr) Daa-pyridine comme ligand des récepteurs périphériques des benzodiazépines pour l'imagerie de diagnostic et le traitement pharmaceutique
CN101522624B (zh) 苯乙烯基吡啶衍生物及其用于结合和成像淀粉样蛋白斑的用途
AU2016206246B2 (en) Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
CA2753532A1 (fr) Derives de nicotinamide
EP2970345B1 (fr) Agents d'imagerie par tep ciblés sur le psma marqués au 18f
ES2431592T3 (es) Métodos y agentes para preparar agentes de fluoración radiomarcados con 18F
US20130012548A1 (en) Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds
AU6708500A (en) Substituted 2-arylbenzazole compounds and their use as antitumour agents
US20190282714A1 (en) Radioligands for imaging the ido1 enzyme
JP4489587B2 (ja) イメージング化合物
WO2013173583A1 (fr) Inhibiteurs de psma
US20110178396A1 (en) Nicotinamide Derivatives
Chen et al. Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: Potential PET imaging agents for tumor detection
Billaud et al. Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma
EP2657213A1 (fr) Dérivés de quinoxaline marqués comme produits radiopharmaceutiques multimodaux et leurs précurseurs
AU2002239099B2 (en) New diaminedithiol derivatives and radiorhenium or radiotechnetium complex thereof; a liver cancer-treating composition comprising the radiorhenium complex and lipiodol; and a kit for preparation of the liver cancer-treating composition
US7041851B2 (en) Fluorinated phenyl thiophenyl derivatives and their use for imaging serotonin transporters
TW202309050A (zh) 用於亨丁頓（ｈｕｎｔｉｎｇｔｉｎ）蛋白造影之氘化化合物及造影劑
CN103797007A (zh) 新合成方法

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20140422